Form 4: Serina Therapeutics CSO Sells Shares After Option Exercise

Serina Therapeutics' Chief Scientific Officer, Randall Moreadith, sold 3,555 shares of common stock after exercising options, as disclosed in a Form 4 filing.

Summary

• Randall Moreadith, Chief Scientific Officer of Serina Therapeutics, Inc., exercised stock options to acquire 3,555 shares of common stock on December 11, 2025.
• The exercise price for these options was $0.06 per share.
• Immediately following the exercise, Mr. Moreadith sold all 3,555 shares of common stock.
• The shares were sold at a weighted average price of $3.2404 per share, with individual transactions ranging from $3.20 to $3.35.
• This transaction was conducted pursuant to a Rule 10b5-1 trading plan.
• Following these transactions, Mr. Moreadith beneficially owns 0 shares of common stock directly and 366,886 stock options directly.

Sentiment

Score: 5

Explanation: The transaction is neutral. While an insider sale can be seen negatively, it was executed under a 10b5-1 plan, indicating a pre-planned liquidity event rather than a reaction to new, negative information. The executive still holds a significant number of options.

Positives

• The Chief Scientific Officer exercised options, indicating a prior belief in the company's value.
• The exercise price of $0.06 per share compared to the sale price of $3.2404 per share demonstrates a significant profit for the insider on these specific shares.

Negatives

• The Chief Scientific Officer sold all shares acquired from the option exercise, reducing their direct common stock ownership to zero.
• Insider sales, even if pre-planned, can sometimes be perceived negatively by the market.

Future Outlook

NA

Industry Context

This transaction is a routine insider filing for an executive at a biotechnology or pharmaceutical company, common for compensation structures involving stock options. It does not provide broader industry context beyond the individual's compensation activity.

Related Party Transactions

• Randall Moreadith, Chief Scientific Officer, engaged in an exercise of stock options and subsequent sale of common stock, which constitutes a related party transaction as an insider trading activity.

Stakeholder Impact

• Shareholders may observe the Chief Scientific Officer's sale of shares, which could be interpreted in various ways, though the 10b5-1 plan mitigates concerns about opportunistic selling. The transaction itself does not directly impact employees, customers, suppliers, or creditors.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-planned insider transaction (option exercise and sale under a 10b5-1 plan) by the Chief Scientific Officer. It does not provide new fundamental information about Serina Therapeutics' operational performance, strategic direction, or financial health that would warrant a change in investment thesis. The executive still retains a substantial number of unexercised options. Therefore, a 'hold' recommendation is appropriate as this filing alone does not present a compelling reason to buy or sell the stock.

Keywords

Serina Therapeutics, SER, Form 4, Insider Trading, Stock Option Exercise, Share Sale, Randall Moreadith, Chief Scientific Officer, 10b5-1 Plan